Federal Center for the Toxicological and Radiation Safety of Animals, All-Russian Institute of Veterinary Research, Kazan, Russia.
Anim Health Res Rev. 2011 Jun;12(1):113-21. doi: 10.1017/S1466252311000028.
During the first half of the twentieth century, widespread regulatory efforts to control cattle brucellosis due to Brucella abortus in the Union of Soviet Socialist Republics were essentially non-existent, and control was limited to selective test and slaughter of serologic agglutination reactors. By the 1950s, 2-3 million cattle were being vaccinated annually with the strain 19 vaccine, but because this vaccine induced strong, long-term titers on agglutination tests that interfered with identification of cattle infected with field strains of B. abortus, its use in cattle was discontinued in 1970. Soviet scientists then began a comprehensive program of research to identify vaccines with high immunogenicity, weak responses on agglutination tests and low pathogenicity in humans, as a foundation for widespread control of cattle brucellosis. While several new vaccines that induced weak or no responses on serologic agglutination tests were identified by experiments in guinea pigs and cattle, a large body of experimental and field studies suggested that the smooth-rough strain SR82 vaccine combined the desired weak agglutination test responses with comparatively higher efficacy against brucellosis. In 1974, prior to widespread use of strain SR82 vaccine, over 5300 cattle farms across the Russian Federation were known to be infected with B. abortus. By January 2008, only 68 cattle farms in 18 regions were known to be infected with B. abortus, and strain SR82 continues to be the most widely and successfully used vaccine in many regions of the Russian Federation.
在 20 世纪上半叶,苏联对布鲁氏菌病(由流产布鲁氏菌引起)的广泛监管努力基本不存在,控制措施仅限于对血清凝集反应阳性的牛进行选择性检测和扑杀。到 20 世纪 50 年代,每年有 200 万至 300 万头牛接种 19 号菌株疫苗,但由于该疫苗在凝集试验中产生强烈、长期的效价,干扰了对田间感染流产布鲁氏菌的牛的识别,因此 1970 年停止在牛中使用。苏联科学家随后开始了一项全面的研究计划,旨在确定具有高免疫原性、在凝集试验中反应较弱且对人类低致病性的疫苗,作为广泛控制牛布鲁氏菌病的基础。虽然通过豚鼠和牛的实验鉴定出了几种在血清凝集试验中产生弱或无反应的新型疫苗,但大量的实验和现场研究表明,光滑-粗糙株 SR82 疫苗结合了所需的弱凝集试验反应和相对较高的布鲁氏菌病防治效果。1974 年,在广泛使用 SR82 疫苗之前,俄罗斯联邦的 5300 多个牛场被认为感染了流产布鲁氏菌。到 2008 年 1 月,仅在 18 个地区的 68 个牛场中发现感染了流产布鲁氏菌,而 SR82 株继续是俄罗斯联邦许多地区使用最广泛和最成功的疫苗。